Economic insights indicate improved quality of life with epcoritamab in the general population, suggesting preferences for its administration.
This study provides early economic insights, based on general population preferences, suggesting that epcoritamab's subcutaneous injection and outpatient administration beyond Cycle 2 may be associated with improved QOL compared to other therapies, regardless of efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Fuji et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: